60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment Of Ability To Meet FDA Requirements
Portfolio Pulse from Benzinga Newsdesk
60 Degrees Pharma has withdrawn its Phase IIB Investigational New Drug (IND) application for a COVID-19 treatment. The company plans to resubmit the application after assessing its ability to meet FDA requirements.
September 18, 2023 | 8:17 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
60 Degrees Pharma, potentially associated with SXTP, has withdrawn its Phase IIB IND for a COVID-19 treatment. The company's ability to meet FDA requirements will be reassessed before resubmission.
The withdrawal of the Phase IIB IND application could potentially delay the development and approval of the company's COVID-19 treatment, which could negatively impact the company's stock price in the short term. However, the company's plan to resubmit the application after reassessing its ability to meet FDA requirements could mitigate this impact in the long term.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100